Anzeige
Mehr »
Samstag, 10.01.2026 - Börsentäglich über 12.000 News
Fundamental stark, Kurs zu niedrig - Chance beim Krebs-Impfstoff-Pionier!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EEZB | ISIN: US72941H5090 | Ticker-Symbol: XMP0
NASDAQ
09.01.26 | 21:57
0,555 US-Dollar
-5,08 % -0,030
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
PLUS THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
PLUS THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur PLUS THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrPLUS THERAPEUTICS, INC. - S-1, General form for registration of securities-
DoPlus Therapeutics completes FDA meeting on REYOBIQ trial strategy2
DoPlus Therapeutics Inc.: Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ for Leptomeningeal Metastases100HOUSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals...
► Artikel lesen
11.12.25Plus Therapeutics Inc.: Plus Therapeutics Expands CNSide Assay Platform to State of California15
09.12.25Plus Therapeutics adds key personnel to CNSide Diagnostics team1
PLUS THERAPEUTICS Aktie jetzt für 0€ handeln
09.12.25Plus Therapeutics Inc.: Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants1
04.12.25Plus Therapeutics Inc.: Plus Therapeutics Highlights Three REYOBIQ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting6
01.12.25Plus Therapeutics to present breast cancer treatment data at SABCS10
26.11.25H.C. Wainwright reaffirms Buy rating on Plus Therapeutics stock at $2.001
26.11.25Plus Therapeutics: H.C. Wainwright bestätigt "Buy"-Rating mit Kursziel 2,00 $4
24.11.25Plus Therapeutics Inc.: Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ in Leptomeningeal Metastases498HOUSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals...
► Artikel lesen
20.11.25Plus Therapeutics Inc.: Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide Cerebrospinal Fluid Assay for Metastatic CNS Cancer4
17.11.25Plus Therapeutics receives Nasdaq extension to meet minimum bid price2
17.11.25Plus Therapeutics Inc.: Plus Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement222HOUSTON, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
► Artikel lesen
17.11.25PLUS THERAPEUTICS, INC. - 8-K, Current Report1
06.11.25Plus Therapeutics Inc.: Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.03
03.11.25Plus Therapeutics stock price target lowered to $2 at H.C. Wainwright6
30.10.25Plus Therapeutics GAAP EPS of -$0.04 misses by $0.01, revenue of $1.4M misses by $0.1M2
30.10.25PLUS THERAPEUTICS, INC. - 10-Q, Quarterly Report2
30.10.25Plus Therapeutics Inc.: Plus Therapeutics Reports Third Quarter Financial Results and Recent Business Highlights167US market introduction of the CNSide® CSF diagnostics platform, with first national coverage agreement with UnitedHealthcare Presented positive RESPECT-LM Ph1 clinical trial results HOUSTON, Oct....
► Artikel lesen
Weiter >>
79 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,3